文献速递妇科

使用更新版预测指数值模型通过影像学与手术评估输卵管卵巢癌不可切除性的前瞻性多中心ISAAC研究

Prediction of nonresectability using the updated Predictive Index value model assessed by imaging and surgery in tubo-ovarian cancer: a prospective multicenter ISAAC study.
PubMed 文献 · Am J Obstet Gynecol · 2024-07-03

这项欧洲前瞻性多中心观察性研究纳入242例疑似输卵管卵巢癌患者,以手术残留灶>1cm为参考标准,比较超声、CT和WB-DWI/MRI基于更新版PIV模型预测不可切除性的效能。超声预测不可切除性的AUC为0.80,CT为0.76,WB-DWI/MRI为0.71,手术探查为0.90;超声非劣效于CT和WB-DWI/MRI,且与术中所见的一致性最高。

要点

  • 超声预测不可切除性的AUC为0.80,CT为0.76,WB-DWI/MRI为0.71,手术探查为0.90。
  • 超声与术中评估更新版PIV模型各参数的一致性最高,Cohen kappa为0.59至0.79。
  • 经专门培训的超声检查者可用超声评估腹部病变并预测不可切除性。

核心结论

  • 超声在区分可切除与不可切除肿瘤方面非劣效于CT和WB-DWI/MRI。
  • 超声在评估更新版PIV模型各参数时与术中所见的一致性最佳。
  • 经专门培训的超声检查者可用超声评估腹部病变并预测不可切除性。

研究设计与样本

  • 欧洲前瞻性多中心观察性研究,2018年至2022年在5个欧洲妇科肿瘤中心开展。
  • 纳入242例疑似输卵管卵巢癌患者,超声和CT为强制指标检查,WB-DWI/MRI为可选检查。
  • 参考标准为手术结局定义的残留灶>1cm,通过腹腔镜和/或开腹手术评估。

主要发现

  • 145/242(59.9%)患者术后无肉眼残留(R0),其中5/145经腹腔镜、140/145经开腹手术。
  • 17/242(7.0%)患者残留肿瘤≤1cm(R1),均经开腹手术。
  • 80/242(33.1%)患者残留肿瘤>1cm(R2),其中30例接受开腹手术并完成最大程度手术,50/80仅接受腹腔镜。
  • 排除18/242(7.4%)接受手术但不适合广泛手术的患者后,在167例女性中分析3种影像学方法的预测效能。
  • 区分可切除与不可切除肿瘤的AUC:超声0.80,CT0.76,WB-DWI/MRI0.71,手术探查0.90。

关键数值与推荐

  • 不可切除性的预测因素为可疑肠系膜回缩和/或小肠粟粒性癌病,或若不存在上述情况则PIV>8(更新版PIV模型)。
  • PIV评分范围为0至12,根据6个预定义腹腔部位(大网膜、肝表面、小网膜/胃/脾、壁层腹膜、膈肌、肠浆膜/肠系膜)的病变存在情况计算。

临床怎么用

  • 经专门培训的超声检查者可用超声评估腹部病变并预测输卵管卵巢癌患者的不可切除性。

局限性

  • WB-DWI/MRI为可选检查,并非所有中心均可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A laparoscopy-based scoring system was developed by Fagotti et al (Fagotti or Predictive Index value (PIV)score) based on the intraoperative presence or absence of carcinomatosis on predefined sites. Later, the authors updated the PIV score calculated only in the absence of one or both absolute criteria of nonresectability (mesenteric retraction and miliary carcinomatosis of the small bowel) (updated PIV model). OBJECTIVE: The aim was to demonstrate the noninferiority of ultrasound to other imaging methods (contrast enhanced computed tomography (CT) and whole-body diffusion-weighted magnetic resonance imaging (WB-DWI)/MRI) in predicting nonresectable tumor (defined as residual disease >1 cm) using the updated PIV model in patients with tubo-ovarian cancer. The agreement between imaging and intraoperative findings as a reference was also calculated. STUDY DESIGN: This was a European prospective multicenter observational study. We included patients with suspected tubo-ovarian carcinoma who underwent preoperative staging and prediction of nonresectability at ultrasound, CT, WB-DWI/MRI, and surgical exploration. Ultrasound and CT were mandatory index tests, while WB-DWI/MRI was an optional test (non-available in all centers). The predictors of nonresectability were suspicious mesenteric retraction and/or miliary carcinomatosis of the small bowel or if absent, a PIV >8 (updated PIV model). The PIV score ranges from 0 to 12 according to the presence of disease in 6 predefined intra-abdominal sites (great omentum, liver surface, lesser omentum/stomach/spleen, parietal peritoneum, diaphragms, bowel serosa/mesentery). The reference standard was surgical outcome, in terms of residual disease >1 cm, assessed by laparoscopy and/or laparotomy. The area under the receiver operating characteristic curve (AUC) to assess the performance of the methods in predicting nonresectability was reported. Concordance between index tests at the detection of disease at 6 predefined sites and intraoperative exploration as reference standard was also calculated using Cohen's kappa. RESULTS: The study was between 2018 and 2022 in 5 European gynecological oncology centers. Data from 242 patients having both mandatory index tests (ultrasound and CT) were analyzed. 145/242 (59.9%) patients had no macroscopic residual tumor after surgery (R0) (5/145 laparoscopy and 140/145 laparotomy) and 17/242 (7.0%) had residual tumor ≤1 cm (R1) (laparotomy). In 80/242 patients (33.1%), the residual tumor was>1 cm (R2), 30 of them underwent laparotomy and maximum surgery was carried out, and 50/80 underwent laparoscopy only, because cytoreduction was not feasible in all of them. After excluding 18/242 (7.4%) patients operated on but not eligible for extensive surgery, the predictive performance of 3 imaging methods was analyzed in 167 women. The AUCs of all methods in discriminating between resectable and nonresectable tumor was 0.80 for ultrasound, 0.76 for CT, 0.71 for WB-DWI/MRI, and 0.90 for surgical exploration. Ultrasound had the highest agreement (Cohen's kappa ranging from 0.59 to 0.79) than CT and WB-DWI/MRI to assess all parameters included in the updated PIV model. CONCLUSION: Ultrasound showed noninferiority to CT and to WB-DWI/MRI in discriminating between resectable and nonresectable tumor using the updated PIV model. Ultrasound had the best agreement between imaging and intraoperative findings in the assessment of parameters included in the updated PIV model. Ultrasound is an acceptable method to assess abdominal disease and predict nonresectability in patients with tubo-ovarian cancer in the hands of specially trained ultrasound examiners.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Moro F, Pinto P, Chiappa V, et al. Prediction of nonresectability using the updated Predictive Index value model assessed by imaging and surgery in tubo-ovarian cancer: a prospective multicenter ISAAC study. Am J Obstet Gynecol. 2024. PMID: 38969200. doi:10.1016/j.ajog.2024.06.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。